BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 36106499)

  • 1. Small non-coding RNA therapeutics for cardiovascular disease.
    Shah AM; Giacca M
    Eur Heart J; 2022 Nov; 43(43):4548-4561. PubMed ID: 36106499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.
    Bejar N; Tat TT; Kiss DL
    Curr Atheroscler Rep; 2022 May; 24(5):307-321. PubMed ID: 35364795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.
    Hennessy EJ; Moore KJ
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):247-54. PubMed ID: 23743768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The infinite possibilities of RNA therapeutics.
    Mollocana-Lara EC; Ni M; Agathos SN; Gonzales-Zubiate FA
    J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34463324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress on RNA-based therapeutics for genetic diseases.
    Luo T; Huo C; Zhou T; Xie S
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 52(4):406-416. PubMed ID: 37643975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-targeted therapeutics in cardiovascular disease: the time is now.
    Krychtiuk KA; Rader DJ; Granger CB
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):94-99. PubMed ID: 36138490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
    Yu AM; Choi YH; Tu MJ
    Pharmacol Rev; 2020 Oct; 72(4):862-898. PubMed ID: 32929000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Types of RNA therapeutics.
    Goleij P; Babamohamadi M; Rezaee A; Sanaye PM; Tabari MAK; Sadreddini S; Arefnezhad R; Motedayyen H
    Prog Mol Biol Transl Sci; 2024; 203():41-63. PubMed ID: 38360005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as targets for antisense-based therapeutics.
    Stenvang J; Kauppinen S
    Expert Opin Biol Ther; 2008 Jan; 8(1):59-81. PubMed ID: 18081537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in microRNA delivery.
    Zhang Y; Wang Z; Gemeinhart RA
    J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
    Pandey M; Ojha D; Bansal S; Rode AB; Chawla G
    Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
    Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
    J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.
    Bajan S; Hutvagner G
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
    Barata P; Sood AK; Hong DS
    Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
    Ling H
    Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic RNA Therapeutics in Cancer.
    Han Y; Shin SH; Lim CG; Heo YH; Choi IY; Kim HH
    J Pharmacol Exp Ther; 2023 Aug; 386(2):212-223. PubMed ID: 37188531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA therapeutics for metabolic disorders.
    Vu TD; Lin SC; Wu CC; Chu DT
    Prog Mol Biol Transl Sci; 2024; 203():181-196. PubMed ID: 38359998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.